Twitter Facebook LinkedIn YouTube

CanniMed Therapeutics (TSX: CMED) New Listing

Video Platform Video Management Video Solutions Video Player

The Canadian-based, international plant biopharmaceutical company, is a leader in the Canadian medical cannabis industry, with 15 years of pharmaceutical cannabis cultivation experience.

Additional Information:

Company: CanniMed Therapeutics
Website: http://www.cannimed.com
Stock Symbol: TSX: CMED
Date Published: Dec 29, 2016
Transcript: Available

Video Transcript:

I’m Samantha Deutscher for Investmentpitch Media

CanniMed Therapeutics (TSX:CMED) is the latest new listing on the Toronto Stock Exchange.

The Canadian-based, international plant biopharmaceutical company, is a leader in the Canadian medical cannabis industry, with 15 years of pharmaceutical cannabis cultivation experience.

The company’s state-of-the-art, GMP-compliant plant production processes, includes 281 points of quality control, and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products.

In addition, the company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

CanniMed Ltd., a wholly-owned subsidiary of the Company, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations
.
Prairie Plant Systems Inc., a wholly-owned subsidiary of the Company, was the sole supplier to Health
Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of diversion.

The company completed an IPO through syndicate led by AltaCorp Capital, including Canaccord Genuity, Clarus Securities, Mackie Research, and Haywood Securities.

The company raised gross proceeds of $60 million, from the sale of 5 million shares at $12.00.

The underwriters were granted an over-allotment option to purchase up to another 750,000 shares at the same price.

Brent Zettl, co-founder and CEO, stated: “CanniMed’s IPO represents a major milestone for the company and provides us with additional capital to support our continued growth, both in Canada and internationally. We believe we are at the early stages of a tremendous growth opportunity for medical cannabis, and CanniMed is focused on becoming the supplier of choice in the medical community and with patients who are looking for consistent, high-quality treatment alternatives in delivery forms that align to traditional methods.”

The shares are trading at $10.50 and with 19.8 million shares outstanding, the company is capitalized at $208 million.

For more information please visit the company’s website www.cannimed.com contact Dara Willis
at 416-836-9272 or email media@cannimed.com.

I’m Samantha Deutscher for Investmentpitch Media